FindTrial
Sign In

Modifying duration of steroid therapy in worm infestation of brain based on initial size

Baseline cyst size guided increase in duration for steroid therapy in viable parenchymal neurocysticercosis a pilot prospective interventional study - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073349
Enrollment
30
Registered
2024-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B690- Cysticercosis of central nervous system

Interventions

Intervention1: Duration of steroid therapy based on baseline cyst size (long arm): Diagnosis will be confirmed as per standard globally accepted criteria and after applying inclusion and exclusion cri

Sponsors

All India Institute of Medical Sciences New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Children and adolescents aged 2-18 years 2.Parenchymal NCC, viable (vesicular/colloidal), up to 5 in number 3.In multiple lesions with sizes less than as well as more than 0.7 cm, it will be included in the 14 days steroid group and only the more than 0.7 cm cyst outcome will be analysed

Exclusion criteria

Exclusion criteria: 1.Received anticysticidal and steroid therapy in the last 6 months 2.Need for repeat steroid therapy within 6 months follow up 3.Raised ICP, cysticercal encephalitis 4.Extra-parenchymal NCC, intra-ocular NCC 5.Critically sick children Co-existing known chronic illness

Design outcomes

Primary

MeasureTime frame
In children and adolescents aged 2-18 years with viable parenchymal NCC (up to 5 lesions), in cysts more than or equal to 0.7 cm, receiving Dexamethasone (0.6 mg/kg/day) for 14 days, to estimate the proportion of resolved cysts at 6 months (+ 1 month) on CECT Head post completion of albendazole and steroid therapyTimepoint: 6 months post therapy—

Secondary

MeasureTime frame
In children and adolescents aged 2-18 years with viable parenchymal NCC (up to 5 lesions), in cysts less than 0.7 cm receiving Dexamethasone (0.6 mg/kg/day) for 5 days, to estimate the proportion of resolved cysts at 6 months (+ 1 month) on CECT Head post completion of albendazole and steroid therapy To estimate breakthrough seizure rates in both the groups over at least 6 months follow up post completion of albendazole and steroid therapyTimepoint: Follow up after 6 months of therapy—

Countries

India

Contacts

Public ContactDr Biswaroop Chakrabarty

All India Institute of Medical Sciences, New Delhi

biswaroopchakrabarty@gmail.com9818260603

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026